Identification of clinical biomarkers for adjuvant chemotherapy in gastric cancer after D2 dissection by pooled analysis of individual patient data from three large randomized clinical trials
- 1 January 2018
- journal article
- Published by The Japanese Society of Strategies for Cancer Research and Therapy in Annals of Cancer Research and Therapy
- Vol. 26 (1) , 43-45
Abstract
We aimed to identify prognostic and predictive markers among clinicopathological factors for efficacy of adjuvant chemotherapy in gastric cancer by pooled analysis from 3,521 patients on three large randomized trials: ACTS-GC, CLASSIC, and SAMIT. The primary endpoint was relapse-free survival, and the secondary endpoints were overall survival. The integrity of individual patient data was verified. Significant prognostic markers in surgery alone groups of ACTS-GC and CLASSIC were lower body mass index and advanced stage of disease.Keywords
This publication has 5 references indexed in Scilit:
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialThe Lancet, 2012
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric CancerJournal of Clinical Oncology, 2011
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001